Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation
Prospective, Randomized, Open, 2-arm National Multi-center Study to Evaluate the Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation.
Sponsor: Heidelberg University
A PHASE2 clinical study on Chronic Allograft Nephropathy and Grafting, this trial is terminated or withdrawn. The trial is conducted by Heidelberg University and has accumulated 6 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Nov 2022 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Dec 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Heidelberg University
- Heinrich-Heine University, Duesseldorf
- Humboldt-Universität zu Berlin
- Martin-Luther-Universität Halle-Wittenberg
- Technical University of Munich
- Transplantationszentrum Köln-Merheim
- University Hospital Freiburg
- University Hospital, Essen
- University of Erlangen-Nürnberg
- University of Jena
- University of Regensburg
For direct contact, visit the study record on ClinicalTrials.gov .